Chimeric antigen receptor (CAR) T-cell therapy involves the modification of genes of patients&rsquo; autologous T-cells to express a CAR, particularly for a tumor antigen, followed by ex vivo cell expansion and re-infusion back to the patient.&nbsp;
&nbsp;
&nbsp;A CAR combines antigen-binding domains-most commonly, a single-chain variable fragment (scFv) derived from the variable domains of antibodies with the signaling domains of the TCR chain and additional costimulatory domains from receptors, such as CD28, OX40, and CD137.&nbsp;
&nbsp;
T-cell genetic modification may occur either via viral-based gene transfer methods or non-viral methods, such as DNA-based transposons, CRISPR/Cas9 technology, zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), or direct transfer of in vitro transcribed-mRNA by electroporation.
&nbsp;
Multiple myeloma is a rare type of cancer, which develops in plasma cells. The patients who are diagnosed with Multiple Myeloma have cancer cells that eventually supersede healthy plasma cells. This process ends the much-needed white blood cells in the body.&nbsp;
&nbsp;
<a style="color: #0066cc; background-color: transparent;" href="https://www.delveinsight.com/report-store/car-t-cell-therapy-for-multiple-myeloma-market" target="_blank" rel="noopener noreferrer">CAR T-Cell Therapy for Multiple Myeloma Market&nbsp;</a>
The Market Size of CAR T-Cell Therapy for Multiple Myeloma in the 6MM is expected to be USD&nbsp;3,766.4&nbsp;Million in 2030.
&nbsp;
Market Drivers&nbsp;
<ul>
<li>Advancements in technology</li>
<li>Increased collaborations and acquisitions</li>
<li>Competition among biotech and pharma giants</li>
</ul>
&nbsp;
Market Barriers&nbsp;
<ul>
<li>Adverse events and toxicity concerns</li>
<li>Regulatory challenges</li>
<li>High cost and low accessibility</li>
</ul>
&nbsp;
CAR T-Cell Therapy for Multiple Myeloma Market Key Players are:-
<ul>
<li>Celgene Corporation</li>
<li>Janssen Research &amp; Development</li>
<li>Poseida Therapeutics</li>
<li>MolMed S.p.A.</li>
<li>Celgene Corporation</li>
<li>Cartesian Therapeutics</li>
<li>CARsgen Therapeutics</li>
<li>Precision BioSciences</li>
</ul>
And many others
&nbsp;
CAR T-Cell Therapy for Multiple Myeloma Emerging Drugs are:-
<ul>
<li>bb2121</li>
<li>JNJ-68284528 (LCAR-B38M)</li>
<li>P-BCMA-101</li>
<li>CAR-CD44v6</li>
<li>JCARH125 (Orvacabtagene autoleucel)</li>
<li>Descartes-08:</li>
<li>CT053</li>
<li>PBCAR269A</li>
</ul>
And many others

CAR T for Multiple myeloma Market

CAR T for Multiple myeloma Symptions, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.